Update in genetic susceptibility in melanoma.
Open accessThe DOI matches its OpenAlex record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Melanoma is the most deadly of the common skin cancers and its incidence is rapidly increasing. Approximately 10% of cases occur in a familial context. To date, cyclin-dependent kinase inhibitor 2A (CDKN2A), which was identified as the first melanoma susceptibility gene more than 20 years ago, is the main high-risk gene for melanoma. A few years later cyclin-dependent kinase 4 (CDK4) was also identified as a melanoma susceptibility gene. The technologic advances have allowed the identification of new genes involved in melanoma susceptibility: Breast cancer 1 (BRCA1) associated protein 1 (BAP1), CXC genes, telomerase reverse transcriptase (TERT), protection of telomeres 1 (POT1), ACD and TERF2IP, the latter four being involved in telomere maintenance. Furthermore variants in melanocortin 1 receptor (MC1R) and microphthalmia-associated transcription factor (MITF) give a moderately increased risk to develop melanoma. Melanoma genetic counseling is offered to families in order to better understand the disease and the genetic susceptibility of developing it. Genetic counseling often implies genetic testing, although patients can benefit from genetic counseling even when they do not fulfill the criteria for these tests. Genetic testing for melanoma predisposition mutations can be used in clinical practice under adequate selection criteria and giving a valid test interpretation and genetic counseling to the individual.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 1×
“TERT is located in 5p15 and encodes the catalytic subunit of the telomerase, which is the ribonucleoprotein complex that maintains telomere length (71).”
BackgroundObesity, cigarette smoking, and telomere length in women
Valdes, A., Andrew, T., Gardner, J., Kimura, M., Oelsner, E., Cherkas, L., Aviv, A., & Spector, T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66630-5 · Cited by 1,363 · cited 2×
“and can be involved in the development of a tumor when the cells are damaged (67-69,72-75).”
BackgroundMeta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., Picconi, O., Boyle, P., & Melchi, C. F. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.016 · Cited by 1,266
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 1×
“MITF is located in the chromosomal region 3p14 and is a master regulator gene of melanocyte development and differentiation, and it is also associated with melanoma development and progression (85).”
BackgroundGermline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“CDK4 was the second high risk melanoma susceptibility gene identified (49).”
BackgroundReduced melanoma after regular sunscreen use: randomized trial follow-up
Green, A. C., Williams, G. M., Logan, V., & Strutton, G. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7078 · Cited by 799 · cited 1×
“Furthermore, a 10-year followup study showed that the daily use of sunscreen reduces the melanoma detection rate, suggesting that regular sunscreen use may prevent melanoma development (12).”
BackgroundPOT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391 · cited 2×
“and can be involved in the development of a tumor when the cells are damaged (67-69,72-75).”
BackgroundMC1R variants, melanoma and red hair color phenotype: A meta‐analysis
Raimondi, S., Sera, F., Gandini, S., Iodice, S., Caini, S., Maisonneuve, P., & Fargnoli, M. C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23396 · Cited by 349
Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345
Cited by
Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
Betti, M., Aspesi, A., Biasi, A., Casalone, E., Ferrante, D., Ogliara, P., Gironi, L. C., Giorgione, R., Farinelli, P., Grosso, F., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.05.011 · Cited by 78
Metadata
- Authors
- Potrony, M., Bádenas, C., Aguilera, P., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., & Puig, S.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2015-09-01
- Volume
- 3
- Issue
- 15
- Pages
- 210-210
- OpenAlex
- W1881660869
- Cited by
- 198
- References
- 13
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update in genetic susceptibility in melanoma. https://app.cochat.ai/papers/10.3978/j.issn.2305-5839.2015.08.11
- The paper
- Potrony, M., Bádenas, C., Aguilera, P., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., & Puig, S. (2015). Update in genetic susceptibility in melanoma. PubMed. https://doi.org/10.3978/j.issn.2305-5839.2015.08.11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.